To learn more, please call our
neuro-oncology department at 513-751-CARE or (888) 649-4800, or visit www.24x7consult.com.
-
- Protocol Title:
- Primary Central Nervous
System Lymphoma
A Phase I/II Study of
Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Treated
with Methotrexate/BBBD, and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin
to the Treatment Regimen
- Protocol Summary:
-
The purpose of this study is to evaluate the
safety and tolerability of chemotherapy delivered in conjunction with a special
technique called blood-brain barrier disruption (BBBD) in patients with primary
central nervous system lymphoma (PCNSL) who have not undergone prior cranial or
spinal radiotherapy. Participants of this study will be hospitalized for
approximately three days every four weeks, to receive chemotherapy. The drug
rituximab will be administered intravenously, the evening prior to carboplatin
(intra-arterial) and methotrexate (intra-arterial) chemotherapy. The two
chemotherapy drugs will be administered in conjunction with BBBD. If the
patient has lymphoma in the eye, chemotherapy will be given into the eye(s) as
well. Participants will receive the drug sodium thiosulfate (intra-venous) four
and eight hours after carboplatin, in an effort to reduce side effects
associated with this chemotherapy regimen. The treatment may continue for up to
12 months in the absence of disease progression or unacceptable side effects.
- Major Eligibility Criteria:
-
- Primary central nervous
system lymphoma (PCNSL)
- No prior cranial or
spinal radiotherapy
- No systemic lymphoma
- No more than 90 days
since diagnosis of PCNSL
- Must be HIV negative
- Must be Hepatitis B and
Hepatitis C negative
- Age 18 to 75 years
- Protocol Title:
- Anaplastic
Oligodendroglioma
Phase I/II Study of
Carboplatin, Melphalan and Etoposide Phosphate in Conjunction with Osmotic
Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate
Chemoprotection, in Subjects with Anaplastic Oligodendroglioma or
Oligoastrocytoma
- Protocol Summary:
-
The purpose of this study is
to evaluate the safety and tolerability of chemotherapy delivered in
conjunction with a special technique called blood-brain barrier disruption
(BBBD) in patients with anaplastic oligodendroglioma or oligoastrocytoma. The
study will also examine the efficacy (one year progression free survival) of
the chemotherapy. Participants of this study will be hospitalized for
approximately three days every four weeks, to receive chemotherapy.
Chemotherapy drugs will include carboplatin (intra-arterial), melphalan
(intra-arterial), and etoposide phosphate (intravenous). The three chemotherapy
drugs will be administered in conjunction with BBBD. Participants will receive
the drug sodium thiosulfate (intravenous) four and eight hours after
carboplatin, in an effort to reduce side effects associated with this
chemotherapy regimen. The treatment may continue for up to 12 months in the
absence of disease progression or unacceptable side effects.
- Major Eligibility Criteria:
-
- Anaplastic
Oligodendroglioma or Oligoastrocytoma
- Prior treatment with
Temozolomide
- Prior consultation with
radiation oncology
- Aged 18 to 75 years old
- Other eligibility
criteria may apply
- Protocol Title:
- High-Grade
Glioma
Phase II Clinical Trial of
Patients with High-Grade Glioma Treated with Intra-arterial Carboplatin-based
Chemotherapy, Randomized to Treatment with or without Delayed Intravenous
Sodium Thiosulfate as a Potential Chemoprotectant against Severe
Thrombocytopenia
- Protocol Summary:
-
The purpose of this study is
to evaluate if the drug called sodium thiosulfate prevents a severe decrease in
a particular type of blood cell (platelets) in patients who are being given
carboplatin, cyclophosphamide, and etoposide phosphate for the treatment of
high-grade glioma. This is a randomized study meaning that neither the
participant nor their doctor may choose to which treatment group the
participant is assigned. All participants of this study receive the
chemotherapy drugs carboplatin (intra-arterial), cyclophosphamide (intravenous)
and etoposide phosphate (intravenous). Participants will be randomized in two groups.
Group 1 will receive the chemotherapy drugs, but not the sodium thiosulfate.
Group 2 will receive the chemotherapy drugs, followed by the sodium thiosulfate
(intravenous), four and eight hours after the chemotherapy.
- Major Eligibility Criteria:
-
- High-grade glioma
- Age 18 to 75 years old
- Other eligibility
criteria may apply